SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 6)

BridgeBio Pharma, Inc.

(Name of Issuer)

Common Stock, par value $0.001 per share

(Title of Class of Securities)

(CUSIP Number)

03/31/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

Names of Reporting Persons

NEIL KUMAR

Check the appropriate box if a member of a Group (see instructions)

(a)

(b)

Sec Use Only

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 4,208,849.00
6	Shared Voting Power 5,074,133.00
7	Sole Dispositive Power 4,208,849.00
8	Shared Dispositive Power 5,074,133.00

Aggregate Amount Beneficially Owned by Each Reporting Person

9,282,982.00

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

Checkbox not checked

Percent of class represented by amount in row (9)

4.6 %

Type of Reporting Person (See Instructions)

Comment for Type of Reporting Person: (1) Consists of (i) 234,451 shares of Common Stock held directly by Dr. Kumar, (ii) 3,903,183 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of March 31, 2026, (iii) 71,215 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of March 31, 2026, (iv) 4,438,447 shares of Common Stock held by the Kumar Haldea Revocable Trust, of which Dr. Kumar is a co-trustee and (v) 635,686 shares of Common Stock held by the Kumar Haldea Family Irrevocable Trust, of which Dr. Kumar is a co-trustee. (2) Percentage ownership is based on (i) 195,707,702 shares of Common Stock outstanding as of March 31, 2026, (ii) 3,903,183 shares of Common Stock underlying stock options held by Dr. Kumar that are exercisable within 60 days of March 31, 2026 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i) and (iii) 71,215 shares of Common Stock underlying restricted stock units held by Dr. Kumar that are subject to vesting and settlement within 60 days of March 31, 2026 and are deemed outstanding pursuant to SEC Rule 13-3(d)(1)(i).

SCHEDULE 13G

Item 1.

(a)

Name of issuer:

BridgeBio Pharma, Inc.

(b)

Address of issuer's principal executive offices:

3160 Porter Street, Suite 250, Palo Alto, California, 94304

Item 2.

(a)

Name of person filing:

NEIL KUMAR

(b)

Address or principal business office or, if none, residence:

3160 Porter Street, Suite 250, Palo Alto, California 94304

(c)

Citizenship:

U.S.

(d)

Title of class of securities:

Common Stock, par value $0.001 per share

(e)

CUSIP No.:

Item 3.

If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a)

Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b)

Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c)

Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d)

Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e)

An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f)

An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g)

A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h)

A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i)

A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j)

A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
please specify the type of institution:

(k)

Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4.

Ownership

(a)

Amount beneficially owned:

9,282,982 shares of Common Stock, which represents (i) 234,451 shares of Common Stock held of record by Dr. Kumar, (ii) 3,903,183 shares of Common Stock issuable to Dr. Kumar upon the exercise of stock options exercisable within 60 days of March 31, 2026, (iii) 71,215 shares of Common Stock issuable to Dr. Kumar upon the vesting and settlement of restricted stock units within 60 days of March 31, 2026, (iv) 4,438,447 shares of Common Stock held of record by Kumar Haldea Revocable Trust and (v) 635,686 shares of Common Stock held of record by the Kumar Haldea Family Irrevocable Trust.

(b)

Percent of class:

4.6%

(c)

Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

4,208,849

(ii) Shared power to vote or to direct the vote:

5,074,133

(iii) Sole power to dispose or to direct the disposition of:

4,208,849

(iv) Shared power to dispose or to direct the disposition of:

5,074,133

Item 5.

Ownership of 5 Percent or Less of a Class.

Ownership of 5 percent or less of a class

Item 6.

Ownership of more than 5 Percent on Behalf of Another Person.

If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.

Not Applicable

Item 7.

Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.

Not Applicable

Item 8.

Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

Not Applicable

Item 9.

Notice of Dissolution of Group.

Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.

Not Applicable

Item 10.

Certifications:

Not Applicable

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

NEIL KUMAR

Signature:	/s/ Neil Kumar
Name/Title:	Neil Kumar
Date:	04/16/2026

Amendment: SEC Form SCHEDULE 13G/A filed by BridgeBio Pharma Inc.